|
Cervical Intraepithelial Neoplasia
|
|
0.010 |
GeneticVariation
|
BEFREE |
CIN significantly increased during TKI treatment in T790M-negative patients and is a candidate resistance mechanism to the first-generation TKIs.
|
31754213 |
2020 |
|
Cervical Squamous Intraepithelial Neoplasia
|
|
0.010 |
GeneticVariation
|
BEFREE |
CIN significantly increased during TKI treatment in T790M-negative patients and is a candidate resistance mechanism to the first-generation TKIs.
|
31754213 |
2020 |
|
Secondary malignant neoplasm of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
T790M detection was associated with higher number of new progressing sites (P = .04), liver progression (P = .002), and a lower frequency of lung metastases (P = .027).
|
31601525 |
2020 |
|
Secondary malignant neoplasm of bone
|
|
0.010 |
GeneticVariation
|
BEFREE |
Plasma T790M status correlated with a higher number of metastatic sites (4 vs. 3, <i>p</i> < .001) and bone metastases (<i>p</i> = .0002).<b>Conclusion:</b> Plasma <i>EGFR</i> T790M testing had shorter TAT compared to tissue testing, however, it was longer than anticipated.
|
31347936 |
2019 |
|
Sarcoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>EGFR</i>-dependent (T790M and C797S mutations) and independent (Mesenchymal Epithelial Transition [<i>MET</i>] gene amplification, Kirsten Rat Sarcoma [<i>KRAS</i>], Phosphatidyl-Inositol 4,5-bisphosphate 3-Kinase Catalytic subunit Alpha isoform [<i>PI3KCA</i>], and RAF murine sarcoma viral oncogene homolog B1 [<i>BRAF</i>] gene mutations) mechanisms of resistance to EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in plasma samples from NSCLC patients using highly sensitive methods (i.e., digital droplet PCR, Next Generation Sequencing), allowing for the switch to other therapies.
|
31416192 |
2019 |
|
Malignant neoplasm of soft tissue
|
|
0.010 |
GeneticVariation
|
BEFREE |
<i>EGFR</i>-dependent (T790M and C797S mutations) and independent (Mesenchymal Epithelial Transition [<i>MET</i>] gene amplification, Kirsten Rat Sarcoma [<i>KRAS</i>], Phosphatidyl-Inositol 4,5-bisphosphate 3-Kinase Catalytic subunit Alpha isoform [<i>PI3KCA</i>], and RAF murine sarcoma viral oncogene homolog B1 [<i>BRAF</i>] gene mutations) mechanisms of resistance to EGFR tyrosine kinase inhibitors (TKIs) have been evaluated in plasma samples from NSCLC patients using highly sensitive methods (i.e., digital droplet PCR, Next Generation Sequencing), allowing for the switch to other therapies.
|
31416192 |
2019 |
|
Hydrothorax
|
|
0.010 |
GeneticVariation
|
BEFREE |
Genomic DNA (gDNA) from tissue and cells in hydrothorax and circulating tumor DNA (ctDNA) from peripheral blood (PB), and clinicopathological data were retrospectively collected from 263 patients who visited Sun Yat-sen University Cancer Center for T790M test.
|
31463130 |
2019 |
|
Primary Lesion
|
|
0.010 |
GeneticVariation
|
BEFREE |
The detection rate of T790M mutations in CSF was 18.1% (2 of 11) in all cases with EGFR-sensitive mutations in the primary lesion.
|
30452286 |
2019 |
|
Lung Diseases, Interstitial
|
|
0.010 |
GeneticVariation
|
BEFREE |
Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease.
|
31371992 |
2019 |
|
progressive non-small cell lung cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Osimertinib has been approved by the Food and Drug Administration (FDA) of the United States (US) for the treatment of progressive non-small cell lung cancer (NSCLC) that has acquired T790M mutation during treatment with first-line epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI).
|
31802642 |
2019 |
|
Tumor Angiogenesis
|
|
0.010 |
GeneticVariation
|
BEFREE |
Disruption of mTORC2 inhibited EGFR/T790M-positive tumor growth in mouse brain and prolonged animal survival correlating a diminished tumor angiogenesis and recruitment of IBA1+ microglia/macrophages in tumor microenvironment.
|
30796032 |
2019 |
|
Leptomeningeal Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Standard-dose osimertinib resulted in a clinically meaningful response in a patient with <i>EGFR</i> T790M-negative 1st generation EGFR TKI refractory leptomeningeal disease.
|
31285867 |
2019 |
|
Multiple Chronic Conditions
|
|
0.010 |
GeneticVariation
|
BEFREE |
Acquired <i>EGFR</i> T790M Mutation After Relapse Following EGFR-TKI Therapy: A Population-based Multi-institutional Study.
|
29715155 |
2018 |
|
Pleural effusion disorder
|
|
0.010 |
GeneticVariation
|
BEFREE |
T790M mutations disappeared from cancer cells in the p</span>leural effusion after a break from the treatment drug and cytotoxic agent administration.
|
30145590 |
2018 |
|
Hashimoto Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
We present a rare case of CASTLE, occurring in association with Hashimoto thyroiditis, with emphasis on cytological features and report for the first time the presence of a low level somatic mutation in EGFR (EGFR T790M mutation).
|
29115061 |
2018 |
|
Signs and Symptoms, Respiratory
|
|
0.010 |
GeneticVariation
|
BEFREE |
This case represents the first evidence that 1) bevacizumab combined with osimertinib can significantly relieve tumor growth and respiratory symptoms in non-small-cell lung cancer patients with osimertinib resistance and 2) the clinical use of osimertinib, bevacizumab, and brigatinib is effective as combination therapy for pulmonary adenocarcinoma in the presence of triple EGFR mutations of L858R, T790M, and <i>cis</i>-C797S.
|
30233215 |
2018 |
|
HER2-positive carcinoma of breast
|
|
0.010 |
GeneticVariation
|
BEFREE |
We developed experimental brain metastasis models by intraventricular injection (intraventricular injection mouse model; IVM) of HER2-positive breast cancer (MDA-MB-361-luc-BR2/BR3) or T790M-EGFR-positive lung cancer (NCI-H1975-luc) cells.
|
29321587 |
2018 |
|
Squamous cell carcinoma of the head and neck
|
|
0.010 |
GeneticVariation
|
BEFREE |
Higher frequency of EGFR-TK domain mutations together with the presence of the T790M mutation suggests that identification of these mutations might streamline the therapy and provide a better prognosis in HNSCC cases.
|
28352186 |
2017 |
|
stage, non-small cell lung cancer
|
|
0.010 |
GeneticVariation
|
BEFREE |
Liquid biopsies (LB) are used routinely in clinical practice in two situations for late stage non-small-cell lung cancer (NSCLC) patients, (i) at the initial diagnosis when looking for activating mutations in EGFR in the absence of analyzable tissue DNA and, (ii) during tumor progression on a tyrosine kinase inhibitor treatment to look for the resistance mutation T790M in EGFR.
|
29069959 |
2017 |
|
Nodule
|
|
0.010 |
GeneticVariation
|
BEFREE |
In this case report, we described a 37-year-old woman who underwent refractory after second-line gefitinib therapy and was confirmed to have SCLC transformation without the T790M mutation in the left lobar nodule, but concomitant with the plasma-genotyped EGFR T790M mutation.
|
28723866 |
2017 |
|
Anaplastic large B-cell lymphoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Extensively validated 3D pharmacophore models for ALK (anaplastic lymphoma kinase) and EGFR (T790M) (epithelial growth factor receptor with acquired secondary mutation) were developed.
|
28290719 |
2017 |
|
Large cell neuroendocrine carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Large Cell Neuroendocrine Carcinoma Transformation and EGFR-T790M Mutation as Coexisting Mechanisms of Acquired Resistance to EGFR-TKIs in Lung Cancer.
|
28778263 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel.
|
28193529 |
2017 |
|
Carcinoma, Spindle-Cell
|
|
0.010 |
GeneticVariation
|
BEFREE |
Using histological and gene sequencing analysis, we observed that the primary adenocarcinoma acquired T790M mutation in EGFR exon 20, and a secondary sarcomatoid carcinoma developed in the vicinity.
|
28786540 |
2017 |
|
MYELOPROLIFERATIVE DISORDER, CHRONIC, WITH EOSINOPHILIA
|
|
0.010 |
GeneticVariation
|
BEFREE |
In conclusion bevacizumab plus EGFR-TKIs could be a valuable treatment for NSCLC patients presenting with MPE upon resistant to EGFR-TKIs therapy, especially for those with acquired T790M mutation.
|
28977977 |
2017 |